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Abstract
In the last three decades, we witnessed a concomitant major increase in lifespan and a
worldwide increasing incidence of chronic diseases such as obesity and type 2 diabetes.
Disruption of energy homeostasis and systemic inflammation appear as common traits
of these epidemic human diseases. The conventional endocannabinoid (eCB) system
encompasses  two G-protein–coupled receptors  (GPCRs),  their  endogenous  ligands
(anandamide and 2-AG), and the enzymes essential for eCB biosynthesis and hydrolytic
inactivation.  Nonetheless,  the  family  of  eCB-like  derivatives  is  growing constantly
including other N-acylethanolamines (NAEs) and 2-monoacylglycerols (2-MAGs) that
do not bind canonical CB receptors rather other orphan G-protein–coupled receptors or
peroxisome proliferator-activated nuclear receptors (PPARs). Here, we focus on the
recent knowledge gathered on one such PPAR endocannabinoid ligand, oleoylethano-
lamide  (OEA),  from the  identification  of  its  synthesis  in  the  small  intestine  to  its
anorexiant  function  with  particular  emphasis  on  our  discovery  of  the  main  brain
neurotransmitters system involved in its satiating effects.
Keywords: dietary fatty acids, histamine, PPARα, GPR119, oxytocin
Abbreviations:
2-arachidonoylglycerol (2-AG); 2-linoleoylglycerol (2-LG); 2-monoacylglycerols (2-MAGs); 2-
oleoyl glycerol (2-OG); 2-palmitoyl glycerol (2-PG); α/β hydrolase domain 6 (ABHD6) and α/
β hydrolase domain 12 (ABHD12); Alzheimer’s disease (AD); amyotrophic lateral sclerosis
(ALS); anandamide (AEA); calcium-dependent N-acyltransferase (Ca-NAT); carnitine palmi-
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toyltransferase-1 (CPT-1); docosahexaenoic acid (DHA); eicosapentaenoic acid (EPA); fatty acids
(FAs); fatty acid amide hydrolase (FAAH); free fatty acids (FFAs); frontotemporal dementia
(FTD); G-protein–coupled receptors (GPCRs); G-protein–coupled receptor 119 (GPR119); GIP
(glucose-dependent  insulinotropic  peptide);glucagon-like  peptide-1  (GLP-1);  histidine
decarboxylase (HDC); long-chain fatty acids (LCFAs); linoleoylethanolamide (LEA); lipoxyge-
nase (LOX); monoacylglycerol lipase (MAGL); medium-chain fatty acids (MCFAs); monoun-
saturated fatty acids (MFAs); N-acylethanolamines (NAEs); N-acylethanolamine hydrolyzing
acid  amidase  (NAAA);  N-acyltransferase  (NAT);  N-arachidonoylethanolamine  (AEA);  N-
acylphosphatidylethanolamine (NAPE); NAPE-hydrolyzing phospholipase D (NAPE-PLD);
nucleus of the solitary tract (NST); N-oleoylethanolamide (OEA); obese (OB); obesity and type
2 diabetes (OBT2D); palmitoylethanolamide (PEA); paraventricular nucleus (PVN);peptide YY
(PYY);  peroxisome  proliferator-activated  receptors  (PPARs);  polyunsaturated  fatty  acids
(PUFAs); pro-opiomelanocortin (POMC); protein kinase C (PKC); retinoid X receptor (RXR);
saturated fatty acids (SFA); stearoylethanolamide (SEA); supraoptic nucleus (SON); transient
receptor potential vanilloid type-1 (TRPV1); triacylglycerols (TAGs); type 2 diabetes (T2D);
uncoupling protein 1 (Ucp1)
1. Introduction
Here the paradox, “although we are entering in the era of super-ageing population and the
expected lifespan is increasing worldwide, overweight and obesity are growing global health
threats in children and adult people.” Western countries and their inhabitants largely contrib-
ute to the scenario. However, although in the United States 35% of the population is obese [1,
2], the rising economies are rapidly filling the gap [3, 4]. In this fatter world, obesity is the major
health challenge that is accountable for multiple medical conditions. With a significant impact
on morbidity and healthcare costs, obesity increases the risk of associated chronic diseases
such as type 2 diabetes (T2D), stroke and heart diseases, hypertension and musculoskeletal
disorders, and many types of cancer [5, 6]. In particular, the association between obesity and
carcinogenesis as in colorectal, pancreatic, prostate, and breast cancer [7] is supported by the
abnormal adipose tissue accumulation and systemic chronic inflammation that characterizes
this condition. The concept of adiposopathy or “fat sickness” well translates the idea of
adipocyte and adipose tissue dysfunction and chronic inflammation that is at the core of
obesity-associated diseases.
Metabolic and neurological disorders have been traditionally viewed independently of one
another and considered involving different etiologies and pathogenesis. However, obesity
during midlife significantly increases the risk of dementias and Alzheimer’s disease (AD) later
in life [8, 9]. Thus, the detrimental accretion of “fat sickness” during aging and the problem of
the defense of cognitive function are linked to unhealthy eating habits and changes in dietary
composition of the current (Westernized) food environment. In the Western diet, not only
complex carbohydrate and fibers, but also “good fat” (e.g., monounsaturated and polyunsa-
turated fats) are replaced in high proportions with easy affordable “bad fats” (e.g., saturated
fats and vegetable oils) and refined sugars. The daily intake of saturated fat (SF) and simple
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sugars increases the risk of impairment of different cognitive functions and accelerate cognitive
decline and AD incidence [10–13].
Unhealthy food can dysregulate the hypothalamic control of energy metabolism and affect
hippocampal-dependent cognition, consequently every bit of knowledge about the mecha-
nisms underlying the effects of nutrients on brain function becomes of primary importance.
In this chapter, we consider the role of endocannabinoid (eCB)-like derivatives as a particular
class of lipids playing a key function in the control of energy intake, adipose tissue metabolism,
management of body weight, and cognitive processing.
2. Obesity culprit of health life in Westernized societies: dietary fatty
acids set the scenario for the lipid sensor oleoylethanolamide
Poor dietary habits (i.e., high-fat diet and refined carbohydrates) negatively contribute to
excessive energy intake, energy accumulation, and consequent dyslipidemia and metabolic
disorders such as obesity and type II diabetes (T2D). Poor dietary habits are considered a
pathogenetic factor for the increasing incidence of cognitive dementias and primarily of AD
[14, 15]. Deciphering the hidden symmetries underlying energy dysfunction in metabolic
syndrome and cognitive decline is one of the main challenges of the next future. Despite the
heterogeneity of its nutrients, the so-called Western diet is a dietary monopoly in which
saturated fats and simple sugars (simple carbohydrates such as mono and disaccharides) are
prevailing.
Indeed, the great convenience and affordability of energy-dense foods that are poor in dietary
fiber and sucrose-rich are liable for the growing incidence of obesity. As a matter of fact, while
dietary fatty acids (FAs) are essential substrates of oxidation and cell energy sources, the
elevated concentration of circulating nonesterified fatty acids (NEFAs) or free fatty acids (FFAs)
has been considered for a long time a marker of obesity and a pathogenetic factor in obesity,
insulin resistance, and etiology of type 2 diabetes [16, 17]. Paradoxically, insulin-sensitive and
highly trained athletes may show ectopic lipid deposition in skeletal muscle [18] proving that
lipid accretion is not the only factor liable for deficient insulin signaling.
It is well known that the presence of double bonds determines the group to which FAs belong,
from saturated fatty acids (SFA) lacking double bonds to one double-bond-containing
monounsaturated fatty acids (MFAs), and polyunsaturated fatty acids (PUFAs) containing at
least two double bonds. FFAs are signaling molecules capable to alter membrane fluidity, lipid
raft, and therefore signal transduction [19]. Different G-protein–coupled receptors (GPCRs)
have been identified to mediate FFA-dependent regulation of several metabolic functions as
for instance by means of their anti- or proinflammatory effects [20]. The identification of several
FFA receptors (FFARs) on the cell surface has allowed clarifying the existence of different
classes of FFARs depending on the length of the carbon chain. Hence, FFA2 (GPR43) and FFA3
(GPR41) receptors are activated by short-chain fatty acids (SCFAs), and FFA1 (GPR40) and
FFA4 (GPR120) receptors are activated by medium- and long-chain fatty acids (MCFAs and
LCFAs, respectively) [21].
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FFAs can also affect metabolism acting as ligands of nuclear hormone receptors such as the
family of peroxisome proliferator-activated receptors (PPARs), which are ligand-activated
transcription factors regulating key genes involved in lipid and nutrient homeostasis and
glucose regulation [22]. PPARs are activated To different degrees by most of FFAs with long
chain PUFAs showing great activation potency and n-3 PUFA eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) as more effective than n-6 fatty acids. For this reason, PPARs are
regarded as energy sensors, master regulators of energy homeostasis [23]. The PPARs family
includes three isoforms, PPARα, PPARβ/δ, and PPARγ(NR1C1, NR1C2, and NR1C3, respec-
tively), differing from one another because of their different tissue distribution, types of
ligands, and physiological effects [23, 24]. Nevertheless, PPARs share a common mode of
action, i.e., the formation of heterodimers with the nuclear receptor retinoid X receptor (RXR)
followed by binding to specific DNA-response elements in target genes [23, 24]. Within this
context, the involvement of PPAR-mediated signaling is critical in neural pathways that are
essential for metabolic adaptivity to energy depletion, in which LCFAs represent the main
energy source [25].
The eCBs are FA derivatives and from this point of view their high affinity for PPARs is not
totally unexpected. The eCB signaling is terminated by specific lipases such as fatty acid amide
hydrolase (FAAH) and N-acylethanolamine hydrolyzing acid amidase (NAAA) for ananda-
mide (AEA) and monoacylglycerol lipase (MAGL), α/β hydrolase domain 6 (ABHD6) and
domain 12 (ABHD12) for 2-arachidonyl glycerol (2-AG) [26, 27]. AEA and 2-AG are derivatives
of n-6 PUFA arachidonic acid (AA) and are hydrolyzed into AA and ethanolamine or AA and
glycerol, respectively [28, 29]. eCB also modulate functions that are independent of the
stimulation of CB1 and CB2 receptors and transient receptor potential vanilloid type-1 (TRPV1)
but are mediated by several “orphan” receptor candidates [30], among which the PPARγ that
binds AEA, delta9-tetrahydrocannabinol, ajulemic acid, and 2-AG [31–34].
In this chapter, our focus is on the PPARα isoform that is highly expressed in tissues under-
going oxidative stress and is characterized by an elevated metabolic activity as in cardiac
muscle, skeletal muscle, intestine, liver, and brown adipose tissue. PPARα activates the
expression of genes involved in fatty acid transport and β-oxidation, thus lowering lipid levels
[35]. It is known that PPARα can be activated by synthetic ligands such as the hypolipidemic
fibrates (e.g., bezafibrate, clofibrate, and fenofibrate) that are part of the treatment of dyslipi-
demia and T2D [36]. In fact, the PPARα is considered a key fatty acids sensor that mediates
lipid metabolism and the effects of FAs and FAs derivatives on gene expression. PPARα is
involved in nutrient metabolism, including the metabolism of lipoproteins, glucose, choles-
terol, and amino acids. Besides FAs, among the endogenous ligands of PPARα there are FA-
like compounds encompassing acyl-CoAs, eicosanoids, eCBs, and eCB-like derivatives [37, 38].
A pioneeristic evidence of the role of PPARα in the effects of eCB derivatives is represented by
the demonstration that fatty acid oxygenases, and in particular the lipoxygenase (LOX)
metabolism of 2-AG can increase the transcriptional activity of PPARα [39]. Soon after these
discoveries, the structural analog of AEA oleoylethanolamide (OEA) appeared on the scene.
OEA belongs to a family of lipid mediators known as fatty acyl ethanolamides or N-acyletha-
nolamines (NAEs) that are FA derivatives possessing an amide bond linking an ethanolamine
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to an acyl group [40–42]. Besides AEA (i.e., N-arachidonoylethanolamine) and OEA (N-
oleoylethanolamide), the NAEs family also includes palmitoylethanolamide (PEA), linoleoy-
lethanolamide (LEA), and stearoylethanolamide (SEA) [43].
Briefly, the complex (and best known) biosynthetic pathways of NAEs initiates from the
common precursor N-acylphosphatidylethanolamine (NAPE) and consists in a two-step
reaction leading first to NAPE formation by transferring the sn-1 fatty acid from a donor
phospholipid to phosphatidylethanolamine by a calcium-dependent N-acyltransferase (Ca-
NAT) [44, 45]. Then, in the second-step, NAPE is hydrolyzed to NAEs via the NAPE-hydro-
lyzing phospholipase D (NAPE-PLD) [45–47]. Interestingly, each NAE is produced by a
corresponding NAPE and those having oleic acid (a monounsaturedn-9 FA) at the amine
position (N-oleoyl-PE) generate OEA [45].
Thus, dietary FA intake directly affects and modulates endogenous OEA levels according to
nutrient (fat) ingestion or food deprivation-induced restriction of OEA synthesis [48]. Dietary
FAs modulate food ingestion in the small intestine (luminal layer) via the increased generation
of oleic acid-containing NAPEs, mobilization of NAPE-PLD as well as via the reduction of
OEA-degrading FAAH activity [49].
OEA is a well-established anorexiant factor, a lipid-based satiety signal whose increase in the
lumen of the small intestine induces a persistent and selective inhibition of food intake without
known adverse reactions [42, 48–52]. Anorexiant agents can curb food ingestion via distinct
mode of action such as the reduction of meal size ingested. Basically, in nonfood deprived
animals, OEA administration increases inter-meal latency (decreasing meal frequency),
whereas it decreases also meal size in food deprived animals [42, 52]. Recently, it has also been
shown that OEA administration induces a clear leftward shifting (an index of early occurrence)
in the temporal development of satiety and the premature onset of satiety [53, 54].
According to the current model of functioning, OEA-mediated satiety signal achieves its
anorexiant effects via a multistep process that (upon OEA formation) initiates in the small
intestinal lumen via the binding to PPARα, of which OEA is a high affinity agonist [49]. This
is further corroborated by the failure of OEA-induced decrease of food intake in mice carrying
the deletion of PPARα [49, 52]. OEA is a nanomolar agonist of the PPARα [55], and this nuclear
receptor is responsible for most of the actions of OEA described so far. In addition, OEA is also
a natural ligand of the G-protein–coupled receptor 119 (GPR119), which is not actually a true
FFAs receptor, such as FFA1, FFA2, and FFA3 (see above), rather a novel target for FAs
derivatives. The orphan GPR119 has been deorphanized by recognizing in the OEA one of its
endogenous high affinity ligands [56]. Besides appetite control, GPR119 is also highly ex-
pressed in pancreatic β cells and involved in glucose-dependent insulin secretion as well as
secretion of gastrointestinal incretin hormone and peptides (glucagon-like peptide-1 (GLP-1)
[57] and GIP (glucose-dependent insulinotropic peptide) from enteroendocrine cells [57]
(Figure 1). GLP-1 has, among other properties, insulinotropic effects inhibition of gastric
emptying, reduction of appetite and promotion of satiety in humans [58] and rodents [59].
Likewise other FAs and FFAs receptors such as GPR120 [60] and FFA1 [61], GPR119 is a lipid
sensing receptor [62] that is activated by oleic acid-containing lipids (e.g., N-oleoyl-dopamine)
and regarded as a potential drug target for the treatment of T2D. In this view, the antidiabetic
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potential of OEA is still unexplored. The ability of OEA to bind the GPR119 is already
demonstrated not to be required for appetite suppression [63]; indeed, deletion of the GPR119
in mice does not prevent the anorexigenic effects of OEA [63, 64]. OEA binding to GPR119
induces secretion of GLP-1 from enteroendocrine L-cells of the ileum [65, 66] and therefore
OEA is an in- vivo GLP-1 secretagogue. Finally, the TRPV1 must be included [67] especially
for its relevance in the “entourage effect” and therefore in the ability to interfere with the eCB
system [68].
Figure 1. Schematic drawing illustrating the putative interactions between OEA, brain regions, and peripheral organs.
OEA activates PPAR-α in the jejunum generating a signal that induces several transcriptional changes leading to in-
creased fatty-acid catabolism, reduced blood lipid levels, and decreased appetite through the activation of brain cen-
ters. OEA signaling travels through vagal afferents to the nucleus of the solitary tract (NST). OEA may also reach the
area postrema (AP; that lacks a tight blood brain barrier) through the circulation. From the NST noradrenergic affer-
ents regulate oxytocin synthesis in the paraventricular (PVN) and supraoptic nucleus (SON) both directly and via the
histaminergic tuberomammillary nucleus (TMN). Efferent neural pathways (for clarity only the sympathetic compo-
nent is shown here) under the control of brain nuclei may alter energy expenditure and peripheral organs’ function.
OEA binds also to GPR119 that are expressed on pancreatic β-cells involved in glucose-dependent insulin secretion, as
well as on enteroendocrine cells that secrete incretins such as glucagon-like peptide-1 (GLP-1).
3. Placing NAEs and 2-MAGs in the framework of the eCB system and
lipid detection: satiety signals and fat sensors
Besides OEA, anorexiant effects have been ascribed also to other NAEs such as PEA and LEA
[69]. This study elegantly demonstrates that high-fat feeding reduces intestinal NAEs levels in
a dose-dependent fashion also supporting the previous idea that such reduction may also
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differently affect OEA, PEA and LEA depending on the type of fat (e.g., oleic Vs palmitic oil)
ingested [70]. Another key point is the observation that orexigenic AEA and 2-AG levels in the
jejunum are upregulated by the arachidonic acid-based diet [70] and that a diet reaching 38%
of energy from fat reduces OEA, PEA, and LEA content, irrespective of dietary fat composi-
tion [70]. This finding demonstrates the critical importance of long-term exposure to high-fat-
like Western diet, rich in saturated (e.g., palmitic acid) and n-6 PUFAs dietary fat. Indeed,
protracted intake of high-fat diet has been hypothesized to increase the luminal content of FAs
and 2-monoacylglycerol thus downregulating the NAT activity lowering the main anorectic
NAEs OEA, PEA and LEA [46]. In turn, decreasing the endogenous levels of lipid signals
conveying information on meal cessation and satiety removes the control brake on high-fat
diet-induced hyperphagia.
The family of eCB-like derivatives includes the additional component of 2-monoacylglycerols
(2-MAGs) among which 2-oleoyl glycerol (2-OG), 2-palmitoyl glycerol (2-PG), and 2-lino-
leoylglycerol (2-LG). Dietary triacylglycerols (TAGs) are the major lipids source for the
stimulation of intestinal incretin hormones release. TAG hydrolysis by pancreas lipase
produces FAs (two molecules) and 2-MAG (one molecule), with the portion of 2-MAG not
degraded contributing to the total levels of 2-MAGs of the intestinal lumen after dietary fat
intake [71, 72].
Although we have previously described the high affinity of OEA for GPR119, it is presently
not clear the extent to which the low endogenous levels of this lipid-derived signal in the
gastrointestinal cells can activate for instance GLP-1 release. Moreover, contrary to the cycles
of feeding deprivation and refeeding [49] that produces opposite changes in OEA levels as
function of NAPE-PLD activity, prolonged dietary fat intake can reduce intestinal NAEs levels.
By contrast, direct effects of dietary fat on incretin secretion (plasma GLP-1 and GIP) have been
shown to occur upon 2-OG administration in (fasting) humans volunteers [73]. More recently,
it has been demonstrated that the GPR119 activation induced by 2-OG can explain the olive
oil-elicited secretion of GLP-1 and peptide YY (PYY) [74]. Similarly, meal rich either in palmitic
or linoleic acids will produce TAG deposit in adipose tissue mostly as 2-PG and 2-LG,
respectively [75].
This opens a scenario where NAEs, and in particular OEA and 2-MAGs, can play together a
concerted (though slightly different) action in fat sensing, lipid detection, and regulation of
dietary fat ingestion via satiety signaling. Assuming GPR119 as a fat sensor [62], the high
binding potency of full agonists such as OEA [56] is not sufficient to predict higher stimulatory
effects on incretin secretion. Although 2-MAGs bind GPR119 less potently than OEA [73] their
elevated intestinal levels will increase the probability of GLP-1 activation, especially for 2-OG.
Moreover, GLP-1 stimulation is higher upon synthesis of 2-OG than 2-PG, further confirming
how much healthier the olive oil-based diet (i.e., Mediterranean diet) can be in comparison
with the saturated fat-rich (e.g., palmitic acid) Western diet. An increase of the intestinal levels
of 2-MAGs has been described as one key factor underlying the insulin sensitizer effects and
antiadipogenic activity of probiotic (Akkermansia muciniphila) treatment in high-fat-fed mice
[76]. One hypothesis suggests that prolonged high-fat diet intake may downregulate the
activity of the NAPE-synthetizing enzyme NAT, thus reducing NAEs levels via a still unknown
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2-MAGs-dependent mechanism [46]. In our opinion, this supports the potential dichotomous
role of 2-MAGs (mainly 2-OG) and NAEs (mainly OEA) that might function as fat sensors and
satiety signaling, respectively.
Despite the important knowledge accumulated regarding the hypothalamic mechanisms
underlying the control of energy homeostasis and the distinct populations of neurons respon-
sible for appetite regulation [77], very little is known about the central pathways responsible
for translating the peripheral information of nutritional status and in orchestrating neural
adaptive responses. For instance, we know that different protein kinase C (PKC) isoforms
(PKC-δ, PKC-ε, and PKC-θ) are required as dietary fat-associated (e.g., LCFA-CoA) signal
transduction pathways and are involved in the development of insulin resistance [78]. In the
following sections, we further examine the notion of brain–gut interface, where the OEA
signaling originates, the role of OEA in energy homeostasis, and the discovery of the main
brain anorexigenic neural pathways engaged by OEA.
4. The notion of brain–gut interface
Fatty acid components are the primary source of calories and constituents of cells and cell
membrane-derived modulators such as eCBs and prostanoids. Evolution has endowed our
species and other mammals of chemical sensors and neuronal machineries to monitor fat intake
and direct foraging behavior to the optimization of fat-rich food collection and consumption.
Therefore, a constant updating of the nutritional status and energy expenditure is required for
the adequate behavioral responses and homeostatic adjustments. This network links not only
peripheral intestinal functions via the production of a number of bioactive molecules with
hypothalamic satiety and hunger centers, but also with brain areas devoted to emotional
responses and cognitive processes. In modern days, though, fat rich food has lost its survival
salience, as it is easily and often inexpensively available to a large part of the population in
Western cultures. In fact, a fatty diet has become one of the major causes of obesity, one of
today’s most blatantly visible – yet most neglected – public health problems. The World Health
Organization coined the term “globesity” [3] to pinpoint the escalating global epidemic of
overweight and obesity, paradoxically coexisting with undernutrition and malnutrition.
How this “gut–brain axis” network works has only partially been elucidated, however some
of the pathways, transmitters, and hormones involved are beginning to be mapped and
discovered.
Sensing for dietary fat, begins in the mouth where taste bud cells of the lingual epithelium are
activated and transmit an initial set of signals to the nucleus of the solitary tract (NST) in the
brain stem [79, 80], and then to brain regions devoted to controlling satiety (e.g., hypothalamic
paraventricular, tuberomamillary, arcuate nuclei) as well as to centers that coordinate reward
related responses such as the nucleus accumbens [80, 81]. Taken together, all these observations
suggest that mammals at least may indeed have a “taste” for fatty food. In the intestine, upon
activation by lipids, specialized chemosensory cells release hormones, peptides, lipid-derived
mediators that relay signals to the brain via hormonal or neuronal pathways [82, 83]. Among
Cannabinoids in Health and Disease150
the membrane sensors expressed by these specialized neurons in the oral and intestinal
epithelium are the CD36 proteins [79, 84], the G-protein–coupled receptors GPR40 and
GPR120 [85]. A decade ago it was discovered that OEA and a subset of structurally similar
FAEs are key components of the molecular machinery responsible for monitoring fat intake in
the small intestine [48]. Fatty acid ethanolamides provide afferent signals from the digestive
tract that travel mostly via vagal afferents [48] to the NST in the brain stem, and activate
hypothalamic brain centers that promote satiety, therefore controlling eating behavior (Figure
1). It appears then, that the NST serves as a relay station where gustatory information carried
by autonomic cephalic nerves, and postingestive information via the vagus nerve converge,
filtering out pleasurable sensations (the cephalic phase that assigns rewarding value to food)
and metabolic responses (reviewed in [80]).
The concept of brain lipid sensing is not new and is related to the problem of brain detection
of body’s nutritional status. In addition to fat sensing hypothalamic nuclei, midbrain, and
hindbrain circuitry can detect glucose levels (glucose sensing neurons), as in pro-opiomela-
nocortin (POMC) neurons of high-fat-fed mice that developed insensitivity to glucose load
and impaired glucose-elicited ATP production [86]. Glucose and lipid sensing are the two main
brain systems for nutrients detection corresponding to insulin and fatty acids signaling acting
to preserve energy homeostasis. Moreover, insulin and fat sensing may act either cooperatively
or independently of each other to inhibit glucose production and appetite, respectively. The
brain lipid sensing system relies on long-chain fatty acids (LCFAs), as lipid signals and oleic
acid infusion within the brain inhibits hepatic glucose production, food intake and elicits
satiety [87, 88]. In the neurons LCFAs are esterified to LCFA-CoA by acyl-CoA synthetase. In
turn, the entry of LCFA-CoA into mitochondria for β-oxidation is regulated by carnitine
palmitoyltransferase-1 (CPT-1). The experimental inhibition of hypothalamic CPT-1 increases
LCFA-CoA neuronal levels and this event is able to reduce glucose production and to promote
premature satiety occurrence [88, 89]. These studies provide evidence that lipid sensing
through the gut–brain axis links together different macromolecules involved in nutrients
sensing and is critical for glucose homeostasis and appetite control. These reports also indicate
that in parallel with the duodenum, LCFA-CoA accumulation is a key event for the inhibition
of energy intake and glucose production. Yet again, in case of prolonged intake of high-fat diet,
LCFA-CoA fails to accumulate and oleic acid does not reduce hepatic glucose production [90,
91], possibly because of the increase in hypothalamic CPT-1 activity. Remarkably, besides gut
nutrient sensing (e.g., intestinal lipid metabolism and cholecystokinin signaling), the brain is
able to detect afferent nutrients and peripheral nutritional status to regulate whole-body
glucose metabolism and energy homeostasis [86, 92–94].
Efferent neural pathways, i.e., the autonomic nervous system and the hypothalamic-pituitary
adrenal axis, under the regulation of the brain may alter energy expenditure and intestinal
function [95]. One such pathway originates in the NST toward the digestive tract facilitating
fat digestion and absorption (Figure 1). Another example of central control of peripheral
functions is provided by the influence exerted by the hypothalamic histaminergic neurons,
one of the key brain systems regulating eating behavior [96, 97] on peripheral homeostatic
responses. Preclinical studies showed that the administration of histamine or of an agonist of
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the histamine H1 receptor in the ventricle or the hypothalamic paraventricular nucleus, where
activation of these receptors induces satiety, increases mRNA expression levels of uncoupling
protein 1 (Ucp1), a marker of energy expenditure, in brown adipose tissue and increases the
electrophysiological activity of sympathetic nerves that innervate it [98, 99]. Also, the central
administration of histamine augments the lipolytic response in white adipose tissue, whereas
pretreatment with a beta adrenergic receptor antagonist blocks the histamine-induced
response, suggesting that the effect is mediated by sympathetic nerves that innervate the white
adipose tissue [100]. Furthermore, it has been recently proposed [101] that neuronal histamine
by activating H1 receptors downregulates hepatic gluconeogenic gene expression. Interest-
ingly, several of these effects are shared by gut-derived OEA. Another efferent pathway was
demonstrated by direct intracerebroventricular infusion of palmitic acid that reduced insulin-
mediated suppression of hepatic insulin production. Furthermore, palmitic acid-enriched diet
activates PKC-θ in the arcuate nucleus and impairs insulin and leptin signaling [102]. This
study elegantly demonstrates the role of PKC-θ activation as one of the pathogenetic mecha-
nisms involved in the genesis of insulin resistance during prolonged high-fat diet intake.
The fascinating aspects of this complex interplay between the intestinal and the central nervous
system is that bioactive molecules generated in the digestive tract signal to the brain not only
the nutritional status, but may affect also cognitive and emotional responses. As a matter of
fact, diet containing balanced PUFAs has become the object of intense research in relation to
cognitive aging and neurodegenerative diseases. In this scenario the potential role of gut
microbiota in influencing brain function, behavior, in the development of the central nervous
system and mental health has recently attracted the attention of neuroscientists and psychia-
trists [103–105]. The relevance of the gut–brain axis in health and disease is becoming manifest
as preclinical and clinical studies are providing new evidence. In a recent report [106],
metabolic changes incorporating fluctuations in weight, insulin resistance, and cholesterol
concentrations in several neurodegenerative disorders, such as amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD) have been observed. The authors raise the intrigu-
ing possibility of a dysregulated homeostatic balance between peripheral and central signals
as partly accountable for the different phenotypes of ALS and FTD patients. In other words,
the authors’ hypothesis is that neurodegenerative processes affecting brain regions necessary
for metabolic regulation concur to the onset of the observed metabolic changes. The gut and
the brain, then, use a plethora of signals to communicate, to monitor and integrate gut functions
as well as to link emotional and cognitive centers of the brain with peripheral intestinal activity.
It is clear then, that gaining insight into this bidirectional communication network on the one
hand poses truly great challenges to the scientific community, on the other it is indispensable
to understand the potential for targeting modifiable risk factors in disease development and
progression.
5. OEA and the control of energy homeostasis
As previously mentioned, OEA signaling is a biosensor for dietary fat that is generated from
oleic acid and conveys a message that translates into a state of satiety characterized by
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prolonged inter-meal intervals and reduced feeding frequency [48]. OEA is also found in
several other organs such as liver, adipose tissue, and brain and its levels can be affected by
short-term feeding of nutrients reminiscent of human diets [70]. However, protein and
carbohydrates do not stimulate OEA mobilization [52]. OEA biological effects are not limited
to moderating food intake, but include stimulation of fat utilization in adipocytes and
hepatocytes [107], of fatty acid absorption in the jejunum [108], of incretins secretion from the
ileum [65]. The effects of OEA on peripheral organs will be dealt in this paragraph, whereas a
separate section will be dedicated to the central actions of OEA.
Digestion of complex dietary lipids in the small-intestinal lumen releases free oleic acid, which
is internalized presumably by the transporter CD36 on the luminal membrane of enterocytes
in the jejunum [109]. Oleic acid is then directed either toward the formation of chylomicrons
or toward the production of OEA through the NAT/NAPE-PLD pathway [109]. Palmitic acid
and linoleic acid as well are taken up presumably by the same transporter CD36 into the
enterocyte and incorporated into NAPE increasing intestinal levels of PEA and LEA, respec-
tively [46]. Surprisingly, diet-induced obese rats and mice, or rats fed with a diet high in NAEs
precursors’ content for over 1 week, had decreased intestinal (not hepatic, nor central) levels
of the three NAEs [110] independently of the type of dietary fatty acid fed to the rats [70]. This
effect is reversible as switching the high-fat diet back to low-fat chow restores the intestinal
levels of OEA, LEA, and PEA to normal within 3 days [111]. Therefore, it appears that excessive
fat intake may render the mechanism dysfunctional, suggesting that suppressing the satiating
effects of gut-derived OEA with a diet rich in fat might contribute to overeating [112].
Food intake and food deprivation also regulate the content of OEA in the jejunum as OEA
levels decrease during food deprivation and increase upon refeeding through a concerted
regulation of OEA biosynthesis and degradation [49]. However, other visceral organs, such as
the liver and pancreas, respond to food deprivation with an increase rather than a decrease in
OEA levels, whereas plasma OEA concentrations is modestly affected, implying that nutrients
regulate OEA mobilization in a tissue-specific manner [49]. The mechanisms by which
nutrients and food deprivation regulate OEA levels in the liver and pancreas is not known,
and the biological significance of such a control is not fully explained. Nonetheless, OEA
appears to have potential therapeutic effects in liver dysfunctions. A direct comparison of the
effect of OEA and fenofibrate (a PPARα agonist used in clinical practice to regulate plasma
lipid disorders) on a rat model of nonalcoholic fatty liver disease showed an improved
protective effect of OEA and a safer profile with respect to the fibrate [113]. OEA reduces liver
triacylglycerol levels and enhances fatty acid oxidation in hepatocytes and these effects are
maintained in mice fed a high-fat diet [107]. The authors suggest that changes in lipid metab-
olism induced by PPARα activation contribute to the weight-reducing action of OEA in obese
mice. Furthermore, in rats OEA regulates several hepatic enzymes including liver fatty acid
binding protein (responsible for uptake and intracellular trafficking of fatty acids) [113] and
the thermogenic uncoupling protein-1 [114]. Also, subchronic administration of a recently
synthesized analog of OEA that binds PPARα receptors, elaidyl-sulfamide, was found to lower
plasma cholesterol and improve the hepatic function of obese rats [115]. Clearly, these
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observations warrant further investigation to fully understand the potential therapeutic of
OEA and congeners in hepatic function.
The available data on the effects of OEA on the adipose tissue suggest that OEA may work in
concert with the sympathetic system to control fat metabolism. The incubation of dissociated
rat and mouse adipocytes with OEA increased the release of nonesterified fatty acids and
glycerol into the extracellular medium in a dose-dependent manner [107]. Of note, a significant
fatty acid mobilization occurred also in vivo after systemic administration of OEA to lean rats.
Conversely, OEA did not change the plasma levels of glucose, insulin, or glucagon, but
markedly increased the transcription of several adipose-tissue genes involved in lipid trans-
port, including CD36 and fatty acid-binding protein [107]. More recently it was reported that
administration of OEA caused a significant fat mass reduction and enhanced energy expen-
diture in rats [114].
One of the first studies in humans showed the potential role of OEA as a regulator of adipose
tissue metabolism in obesity and type II diabetes [116]. The study evaluated the levels of
endocannabinoids such as AEA, 2-AG, OEA and PEA in the subcutaneous adipose tissue of
subjects with both obesity and type II diabetes (OBT2D) and nondiabetic obese (OB) vs normal
subjects. All participants in the study showed similar adiposity and whole-body insulin
resistance and lower plasma leptin levels when compared with normal controls. However, the
levels of OEA, PEA, 2-AG, and AEA were all altered only in OBT2D, but not in OB as compared
with normal subjects [116]. The authors suggest that such alterations might contribute to a
redistribution of fat accumulation in the subcutaneous adipose tissue relative to visceral
adipose tissue and to metabolic dysfunctions that, along with impaired insulin release and
sensitivity, are typical of OBT2D patients [116].
6. From gut to the brain: OEA signaling engages the anorexigenic neural
pathways
The extensive body of preclinical literature presented so far provides undisputable evidence
that OEA functions as a homeostatic signal that regulates metabolic functions, and causes a
long-lasting inhibition of food intake in rats, mice, and humans as well [48, 55, 117, 118].
OEA produces its anorexic effects through a mechanism mediated by the vagus nerve, as the
hypophagic effect is prevented after vagotomy or reversible blockade of the NST a brain stem
area that receives vagal inputs, and it is ineffective when infused directly in the cerebral
ventricles [48]. A recent study, though, challenged this suggestion as it reported that in rats
that received a subdiaphragmatic vagotomy, OEA maintained its hypophagic effect [119].
Clearly, these inconsistencies require further elucidations. In addition to the vagus nerve, a
descending sympathetic pathway originating in the rostral ventrolateral medulla that sends
noradrenergic projections to the intestine and other visceral organs, contributes to OEA
signaling. Surgical disconnection of this pathway impairs the ability of intraduodenal fat
infusions to reduce food intake and inhibits the food-induced OEA synthesis in the jejunum
[120].
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The central neurotransmitter systems recruited by peripheral OEA to inhibit food intake is
beginning to be unraveled. Exogenous administration of OEA increases transcription of the
early gene c-Fos, a marker of neuronal activation, in the NST [48], it increases c-Fos mRNA
and protein expression in oxytocin-immunoreactive neurons in the paraventricular (PVN) and
supraoptic nucleus (SON) [42, 53] in the histaminergic tuberomammillary nucleus [53] and in
the area postrema [121], a circumventricular organ that lacks a functional blood brain barrier
(Figure 1). This latter observation suggests a direct action of OEA in the brain stem by reaching
the area postrema from the blood stream [42].
The activation of PVN and SON is paralleled by increased oxytocin mRNA levels, increased
peptide neurosecretion, and elevated circulating oxytocin levels [42, 53] (Figure 1).In addition,
pharmacological blockade of central oxytocin receptors abolishes the hypophagic effects of
OEA [42], implying that release of oxytocin in the hypothalamus and/or other brain regions is
an obligatory effector of OEA-induced satiety. A noradrenergic pathway from the NST to the
hypothalamus seems to mediate OEA effects on feeding behavior and on hypothalamic
oxytocin increase, as demonstrated in rats with chemical lesions of hindbrain noradrenergic
neurons [122]. Accordingly, in rats, peripheral administration of OEA increases noradrenaline
concentrations in the hypothalamus [123]. Recently, we reported that OEA requires the
integrity of the central histaminergic system to fully exert its hypophagic effect [53]. Brain
histamine has long been known as a mediator of satiety through activation of hypothalamic
histamine H1 receptors [95–97]. In our study [53] we report that mice deficient of the histamine
synthesizing enzyme histidine decarboxylase (HDC–/– mice), or pharmacologically deprived
of releasable brain histamine did not respond to the hypophagic effect of exogenously
administered OEA as normal mice did. We also found that OEA increased c-Fos protein
expression in oxytocin neurons of the PVN of wild type, but not HDC–/– mice, suggesting that
oxytocin rich nuclei are the likely brain region where histaminergic and OEA indirect signaling
converge (Figure 1). In this context, it is important to note that OEA does not induce condi-
tioned taste aversion in rats and does not produce behaviors that are indicative of a state of
fear or anxiety as it does not change plasma corticosterone levels [124]. Hence, we may exclude
that OEA hypophagic actions are attributable to stress or malaise. In fact, the exogenous
subchronic oral administration of OEA in rats was shown to have an antidepressant-like action,
an effect that is attributed to OEA-induced changes in cerebral noradrenaline and serotonin
contents [125].
Despite no data are available indicating that OEA may subserve a neuromodulatory role in
the brain, it has been reported that PPARα activity modulates the firing rate of dopaminergic
neurons in the rat midbrain through a fast effect on nicotinic receptors [126]. These observa-
tions are suggestive of a role of OEA in the modulation of reward and hedonic, nonhomeostatic
functions related to the salience of food-related stimuli.
It is well established that stress hormones activated by emotional arousal enhance memories
associated with emotional events [127]. Hormonal and neural signaling elicited by feeding as
well enhance the consolidation of recent experiences [128]. In this elegant work, the authors
used two distinct experimental paradigms in rats to test consolidation of aversive and spatial
memories, namely the inhibitory avoidance and the Morris water maze, and found that
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systemic administration of OEA after training strongly improved the retention of these tasks.
The memory-enhancing signal generated by OEA apparently activates the brain via the
noradrenergic pathway that generates from NST and provides innervation of the basolateral
amygdala, being this a pathway crucially implicated in the consolidation of recent emotional
memories [129]. It is conceivable, then, that OEA mobilized in the gut after a fat-rich meal
initiates an integrated response that prompts enhanced encoding of information about the
spatial and emotional context in which the meal was consumed [130]. Synthetic PPARα
agonists and inhibitor of FAAHs as well seem to ameliorate memory acquisition in a passive
avoidance task in rats [131].
7. Conclusions
The evidence accumulated over the past years strongly support the notion that OEA mediates
nutrient- and lipid-specific satiety, fatty acids absorption in enterocytes, lipolysis in adipose
tissue, liver and skeletal myocytes, and thermogenic responses [48, 107, 108, 114]. Furthermore,
we recently established that the eCB-derivative OEA engages the brain histaminergic [53] and
oxytocinergic [42, 53] system to induce satiety and suppression of food intake (Figure 1). This
study uncovers previously unidentified neural signaling mechanisms involved in the anorectic
action of OEA and offers new perspectives for the development of more effective and safer
pharmacotherapies to treat obesity and ameliorate the profile of centrally acting drugs [53].
OEA is an ethanolamide of long-chain unsaturated FAs that appears to fulfill most of the
criteria used to classify the antiobesity medications, among which safety is of primary
importance. Moreover, OEA is an anorexigenic factor that can curb energy intake, stimulate
sympathetic activity, and control body weight. Thus, the possibility to investigate the role of
OEA in obese patients might not be speculative anymore. A meal rich in oleic acid increases
OEA plasma levels in healthy volunteers also reducing the total energy intake 3 hours after
oleic acid ingestion [118]. In a recent study [132] on obese patients, it was found that plasma
OEA levels positively correlated with body mass index (BMI) whereas an inverse correlation
was observed between obesity andbrain areas activity (e.g., insula) associated with reward-
signaling. Chronic consumption of “obesogenic” high-fat food can dampen dopamine-
mediated signaling of reward and disrupt the relationship between palatable food-associated
hedonic eating and neural correlates of reward processing [133–135]. The negative correlation
between insular activity and OEA plasma levels in obese subjects raises the possibility that
OEA may be involved in the suppression of food-associated liking reaction and that obesity
might disturb this function. OEA synthesis is disrupted after prolonged high-fat intake but
OEA administration can restore striatal dopamine release and lipid signaling in the gut and
increase the hedonic value of less caloric food [136]. Collectively, these data broaden the
potential of OEA as dietary fat-derived satiety signal involved in homeostatic feeding as well
as in the regulation of hedonic eating.
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